{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:45:51Z","timestamp":1789523151391,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T00:00:00Z","timestamp":1593734400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T00:00:00Z","timestamp":1593734400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s12020-020-02396-0","type":"journal-article","created":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T09:04:40Z","timestamp":1593767080000},"page":"307-313","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A time to revisit the two oldest prandial anti-diabetes agents: acarbose and repaglinide"],"prefix":"10.1007","volume":"70","author":[{"given":"Parisa","family":"Pishdad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Pishdad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gholam Reza","family":"Pishdad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunes","family":"Panahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,3]]},"reference":[{"key":"2396_CR1","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.2337\/dc11-0632","volume":"34","author":"M Riddle","year":"2011","unstructured":"M. Riddle, G. Umpierrez, A. DiGenio et al. Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes. Diabetes Care 34, 2508\u20132514 (2011)","journal-title":"Diabetes Care"},{"key":"2396_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1475-2840-8-23","volume":"8","author":"K Node","year":"2009","unstructured":"K. Node, T. Inoue, Postprandial hyperglycemia as an etiological factor in vascular failure. Cardiovasc. Diabetol. 8, 23 (2009)","journal-title":"Cardiovasc. Diabetol."},{"key":"2396_CR3","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1093\/eurheartj\/ehv239","volume":"36","author":"E Ferrannini","year":"2015","unstructured":"E. Ferrannini, R.A. DeFronzo, Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Eur. Heart J. 36, 2288\u20132296 (2015)","journal-title":"Eur. Heart J."},{"key":"2396_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000439364","volume":"31","author":"A Melmer","year":"2016","unstructured":"A. Melmer, M. Laimer, Treatment goals in diabetes. Endocr. Dev. 31, 1\u201327 (2016)","journal-title":"Endocr. Dev."},{"key":"2396_CR5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11883-018-0740-z","volume":"20","author":"LI Igel","year":"2018","unstructured":"L.I. Igel, K.H. Saunders, J.J. Fins, Why weight? An analytic review of obesity management, diabetes prevention, and cardiovascular risk reduction. Curr. Atheroscler. Rep. 20, 39 (2018)","journal-title":"Curr. Atheroscler. Rep."},{"key":"2396_CR6","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.2337\/dc14-1630","volume":"38","author":"L Van Gaal","year":"2015","unstructured":"L. Van Gaal, A. Scheen, Weight management in type 2 diabetes: current and emerging approaches to treatment. Diabetes Care 38, 1161\u20131172 (2015)","journal-title":"Diabetes Care"},{"key":"2396_CR7","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.2174\/0929867324666170530075533","volume":"25","author":"I Eleftheriadou","year":"2018","unstructured":"I. Eleftheriadou, P. Grigoropoulou, E. Liberopoulos, S. Liatis, A. Kokkinos, N. Tentolouris, Update on cardiovascular effects of older and newer anti-diabetic medications. Curr. Med. Chem. 25, 1549\u20131566 (2018)","journal-title":"Curr. Med. Chem."},{"key":"2396_CR8","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s13300-016-0188-5","volume":"7","author":"M Bannister","year":"2016","unstructured":"M. Bannister, J. Berlanga, Effective utilization of oral hypoglycemic agents to achieve individualized HbA1C targets in patients with type 2 diabetes mellitus. Diabetes Ther. 7, 387\u2013399 (2016)","journal-title":"Diabetes Ther."},{"key":"2396_CR9","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s40200-019-00449-4","volume":"18","author":"M Toroski","year":"2019","unstructured":"M. Toroski, A. Kebriaeezadeh, A. Esteghamati, A.K. Karyani, H. Abbasian, S. Nikfar, Patient and physician preferences for type 2 diabetes medications: a systematic review. J. Diabetes Metab. Disord. 18, 643\u2013656 (2019)","journal-title":"J. Diabetes Metab. Disord."},{"key":"2396_CR10","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1016\/j.jval.2018.05.001","volume":"21","author":"Y Wang","year":"2018","unstructured":"Y. Wang, M. Perri 3rd, A. Systematic, Review of patient-reported satisfaction with oral medication therapy in patients with type 2 diabetes. Value Health 21, 1346\u20131353 (2018)","journal-title":"Value Health"},{"key":"2396_CR11","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.amjms.2020.01.011","volume":"359","author":"R Pishdad","year":"2020","unstructured":"R. Pishdad, P. Pishdad, G.R. Pishdad, Acarbose vs. repaglinide in diabetes treatment: a new appraisal of two old rivals. Am. J. Med. Sci. 359, 212\u2013217 (2020)","journal-title":"Am. J. Med. Sci."},{"key":"2396_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0122795","volume":"10","author":"NC Shuyu","year":"2015","unstructured":"N.C. Shuyu, M.P. Toh, Y. Ko, J. Yu-Chia Lee, Direct medical cost of type 2 diabetes in singapore. PLoS ONE 10, e0122795 (2015)","journal-title":"PLoS ONE"},{"key":"2396_CR13","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.vhri.2015.03.012","volume":"6","author":"S Gu","year":"2015","unstructured":"S. Gu, Z. Tang, L. Shi, M. Sawhney, H. Hu, H. Dong, Cost-minimization analysis of metformin and acarbose in treatment of type 2 diabetes. Value Health Reg. Issues 6, 84\u201388 (2015)","journal-title":"Value Health Reg. Issues"},{"key":"2396_CR14","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s10198-015-0750-5","volume":"17","author":"A M\u00fchlbacher","year":"2016","unstructured":"A. M\u00fchlbacher, S. Bethge, What matters in type 2 diabetes mellitus oral treatment? A discrete choice experiment to evaluate patient preferences. Eur. J. Health Econ. 17, 1125\u20131140 (2016)","journal-title":"Eur. J. Health Econ."},{"key":"2396_CR15","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/S2213-8587(18)30233-X","volume":"6","author":"PURE investigators","year":"2018","unstructured":"PURE investigators, Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study. Lancet Diabetes Endocrinol. 6, 798\u2013808 (2018)","journal-title":"Lancet Diabetes Endocrinol."},{"key":"2396_CR16","first-page":"678","volume":"21","author":"NC Sacks","year":"2015","unstructured":"N.C. Sacks, J.F. Burgess, H.J. Cabral, M.E. McDonnell, S.D. Pizer, The effects of cost sharing on adherence to medications prescribed for concurrent use: do definitions matter? J. Manag. Care Spec. Pharm. 21, 678\u2013687 (2015)","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"2396_CR17","doi-asserted-by":"publisher","first-page":"655","DOI":"10.3111\/13696998.2016.1151795","volume":"19","author":"W Weng","year":"2016","unstructured":"W. Weng, Y. Liang, E.S. Kimball, T. Hobbs, S. Kong, B. Sakurada, J. Bouchard, Drug usage patterns and treatment costs in newly-diagnosed type 2 diabetes mellitus cases, 2007 vs 2012: findings from a large US healthcare claims database analysis. J. Med. Econ. 19, 655\u2013662 (2016)","journal-title":"J. Med. Econ."},{"key":"2396_CR18","doi-asserted-by":"publisher","first-page":"82","DOI":"10.4103\/0976-0105.121653","volume":"4","author":"KG Acharya","year":"2013","unstructured":"K.G. Acharya, K.N. Shah, N.D. Solanki, D.A. Rana, Evaluation of antidiabetic prescriptions, cost and adherence to treatment guidelines: a prospective, cross-sectional study at a tertiary care teaching hospital. J. Basic Clin. Pharm. 4, 82\u201397 (2013)","journal-title":"J. Basic Clin. Pharm."},{"key":"2396_CR19","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.amjms.2016.01.019","volume":"351","author":"JJ Sterrett","year":"2016","unstructured":"J.J. Sterrett, S. Bragg, C.W. Weart, Type 2 diabetes medication review. Am. J. Med. Sci. 351, 342\u2013355 (2016)","journal-title":"Am. J. Med. Sci."},{"key":"2396_CR20","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1177\/1060028014558289","volume":"49","author":"L Tran","year":"2015","unstructured":"L. Tran, A. Zielinski, A.H. Roach et al., Pharmacologic treatment of type 2 diabetes: oral medications. Ann. Pharmacother. 49, 540\u2013556 (2015)","journal-title":"Ann. Pharmacother."},{"key":"2396_CR21","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.mcna.2016.03.014","volume":"4","author":"JJ Wright","year":"2016","unstructured":"J.J. Wright, T.S. Tylee, Pharmacologic therapy of type 2 diabetes. Med. Clin. North. Am. 4, 647\u2013663 (2016)","journal-title":"Med. Clin. North. Am."},{"key":"2396_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.mam.2018.10.004","volume":"66","author":"JM Pappachan","year":"2019","unstructured":"J.M. Pappachan, C.J. Fernandez, E.C. Chacko, Diabesity and antidiabetic drugs. Mol. Aspects Med. 66, 3\u201312 (2019)","journal-title":"Mol. Aspects Med."},{"key":"2396_CR23","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.phrs.2016.11.005","volume":"115","author":"M Ruscica","year":"2017","unstructured":"M. Ruscica, L. Baldessin, D. Boccia, G. Racagni, N. Mitro, Non-insulin anti-diabetic drugs: an update on pharmacological interactions. Pharmacol. Res. 115, 14\u201324 (2017)","journal-title":"Pharmacol. Res."},{"key":"2396_CR24","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.2174\/1568026616666160414123500","volume":"16","author":"RK Singla","year":"2016","unstructured":"R.K. Singla, R. Singh, A.K. Dubey, Important aspects of post-prandial antidiabetic drug, acarbose. Curr. Top. Med. Chem. 16, 2625\u20132633 (2016)","journal-title":"Curr. Top. Med. Chem."},{"key":"2396_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2217\/pgs.14.152","volume":"16","author":"M Chen","year":"2015","unstructured":"M. Chen, C. Hu, W. Jia, Pharmacogenomics of glinides. Pharmacogenomics 16, 45\u201360 (2015)","journal-title":"Pharmacogenomics"},{"key":"2396_CR26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/BF03345682","volume":"32","author":"C Duran","year":"2009","unstructured":"C. Duran, E. Tuncel, C. Ersoy et al., The investigation of the efficacy of insulin glargine on glycemic control when combined with either repaglinide or acarbose in obese type 2 diabetic patients. J. Endocrinol. Invest. 32, 69\u201373 (2009)","journal-title":"J. Endocrinol. Invest."},{"key":"2396_CR27","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1185\/03007990802711024","volume":"25","author":"G Derosa","year":"2009","unstructured":"G. Derosa, S.A. Salvadeo, A. D\u2019Angelo, I. Ferrari, R. Mereu, I. Palumbo, P. Maffioli, S. Randazzo, A.F. Cicero, Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial. Curr. Med. Res. Opin. 25, 607\u20136015 (2009)","journal-title":"Curr. Med. Res. Opin."},{"key":"2396_CR28","doi-asserted-by":"publisher","first-page":"72700","DOI":"10.18632\/oncotarget.20282","volume":"8","author":"SL Wang","year":"2017","unstructured":"S.L. Wang, W.B. Dong, X.L. Dong, W.M. Zhu, F.F. Wang, F. Han, X. Yan, Comparison of twelve single-drug regimens for the treatment of type 2 diabetes mellitus. Oncotarget 8, 72700\u201372713 (2017)","journal-title":"Oncotarget"},{"key":"2396_CR29","first-page":"137","volume":"17","author":"C Rosak","year":"2004","unstructured":"C. Rosak, U. Hofmann, O. Paulwitz, Modification of beta-cell response to different postprandial blood glucose concentrations by prandial repaglinide and combined acarbose\/repaglinide application. Diabetes Nutr. Metab. 17, 137\u2013142 (2004)","journal-title":"Diabetes Nutr. Metab."},{"key":"2396_CR30","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3111\/13696998.2015.1109518","volume":"19","author":"T Lokhandwala","year":"2016","unstructured":"T. Lokhandwala, N. Smith, C. Sternhufvud, E. S\u00f6rstadius, W.C. Lee, J. Mukherjee, A retrospective study of persistence, adherence, and health economic outcomes of fixed-dose combination vs. loose-dose combination of oral anti-diabetes drugs. J. Med. Econ. 19, 203\u2013312 (2016)","journal-title":"J. Med. Econ."},{"key":"2396_CR31","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.ijcard.2016.11.022","volume":"228","author":"YC Lee","year":"2017","unstructured":"Y.C. Lee, C.H. Chang, Y.H. Dong, J.W. Lin, L.C. Wu, J.S. Hwang, L.M. Chuang, Comparing the risks of hospitalized heart failure associated with glinide, sulfonylurea, and acarbose use in type 2 diabetes: a nationwide study. Int. J. Cardiol. 228, 1007\u20131014 (2017)","journal-title":"Int. J. Cardiol."},{"issue":"Suppl 1","key":"2396_CR32","doi-asserted-by":"publisher","first-page":"25","DOI":"10.4158\/EP.12.S1.25","volume":"12","author":"JL Chiasson","year":"2006","unstructured":"J.L. Chiasson, Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial. Endocr. Pract. 12(Suppl 1), 25\u201330 (2006)","journal-title":"Endocr. Pract."},{"key":"2396_CR33","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1080\/14740338.2016.1195368","volume":"15","author":"LM Younk","year":"2016","unstructured":"L.M. Younk, E.M. Lamos, S.N. Davis, Cardiovascular effects of anti-diabetes drugs. Expert Opin. Drug Saf. 15, 1239\u20131257 (2016)","journal-title":"Expert Opin. Drug Saf."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-020-02396-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-020-02396-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-020-02396-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T18:29:05Z","timestamp":1603391345000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-020-02396-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,3]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["2396"],"URL":"https:\/\/doi.org\/10.1007\/s12020-020-02396-0","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,3]]},"assertion":[{"value":"26 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}